Aptose Biosciences Inc (APTO)

[dcaf7]

December corporate presentation posted. Most important info is on slide 26, "$10M financing combined with the $4M 2nd tranche from Hanmi extends cash runway to the end of Q3/2024 and delivers data from TUS/VEN Doublet in AML by 2Q/2024". This slide shows that they are still planning to initiate an MDS trial in 2023. Good luck. They have three days left to accomplish it. And of course, a delay. Now TUS/VEN/HMA triplet pilot arm for 1L AML will start in 2ndQ24. In ESH presentation, it was end of 2023. Slide 5 shows CR rate for patients with prior-VEN failures demonstrated in other studies. In one study, it was 15%, almost same as for TUS/VEN combination in Flt3 WT patients. It is important, since they need to establish and negotiate with FDA a certain CR rate to beat in pivotal study.